Xadu 20 mg (Tablet)
Unit Price: ৳ 200.00 (1 x 10: ৳ 2,000.00)
Strip Price: ৳ 2,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Roxadustat |
| Company | Beximco pharmaceuticals ltd |
| Also available as |
Product Title
- Xadu
Categories
- Medicine
- Anemia Treatment
- Hypoxia-inducible factor prolyl hydroxylase inhibitor
Indications
- Treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adult patients
Description
- First-in-class orally administered HIF-PH inhibitor that promotes erythropoiesis through increasing endogenous production of erythropoietin, improving iron regulation, and overcoming EPO-suppressive effects of inflammation on hemoglobin synthesis and red blood cell production by downregulating hepcidin
Pharmacology
- Orally bioavailable HIF-PH inhibitor with potential anti-anemic activity
- Binds to and inhibits HIF-PH, preventing HIF breakdown and promoting HIF activity
- Increases endogenous erythropoietin production, enhances erythropoiesis, reduces hepcidin expression, improves iron availability, and boosts hemoglobin levels
Dosage & Administration
- Orally taken three times per week (not on consecutive days)
- Individualized dose to maintain target Hb levels of 10-12 g/dL
- Different starting doses for patients not on erythropoiesis-stimulating agent treatment and switching from erythropoiesis-stimulating agents
- Dose adjustment guidelines
- Method of administration - oral intake with or without food
Interactions
- Potential drug-drug interactions with phosphate binders, gemfibrozil, probenecid, and OATP1B1 or BCRP substrates
- Recommendations for adjusting dose based on Hb monitoring
Side Effects
- Common adverse reactions include hypertension, vascular access thrombosis, diarrhea, peripheral edema, hyperkalemia, and nausea
Pregnancy & Lactation
- Contraindicated during pregnancy and breastfeeding
Precautions & Warnings
- Caution in use due to potential initiation of thrombotic vascular events (TVEs)
- Avoid in patients with pre-existing risk factors for TVE, history of seizures, serious signs of infection, or liver disorder
- Avoid initiation in pregnant women
Use in Special Populations
- Not indicated in children
- Not recommended in severe hepatic impairment
Overdose Effects
- Symptoms include increased heart rate transient and likely excessive hemoglobin concentration
- Management with appropriate dose reduction or interruption, not removed by dialysis
Therapeutic Class
- Drugs for Haemolytic Hypoplastic & Renal Anemia
Storage Conditions
- Store in a cool, dry place below 30°C, away from light and moisture, out of reach of children